Show results for
Refine by
Preclinical Modeling Equipment & Supplies In Portugal
112 equipment items found
by:Genmab A/S based inCopenhagen V, DENMARK
In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody®-CD38. In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
The SPOR COV™ product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. SPOR-COV™ has already been shown by SporeGen to provide complete (100%) protection in preclinical models of ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Targeted and selective inhibition of SIK proteins brings an opportunity to restore the immune balance that is typically out of balance in autoimmune diseases. .We have observed encouraging activity in various inflammatory preclinical models with compounds targeting this ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC399 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP), intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration. A Phase I/II ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis. ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop ...
by:Healx Ltd. based inCambridge, UNITED KINGDOM
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to patients ...
Manufactured by:Elpiscience based inShanghai, CHINA
OX40, also known as CD134, is a member of the tumor necrosis factor (TNF) receptor family and is an important co-stimulator of T cell responses. Typically for TNF receptor family members, 3 molecules of OX40 bind to the trimeric OX40 ligand-protein, activating downstream NF-κB, PI3K, and AKT pathways, which lead to increased cytokine production. Activation of OX40 enhances T-cell expansion, ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor activity in several ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Many of the childhood-onset intractable epilepsy conditions within the expanded access program share considerable overlap with ASD and these conditions often fall within the orphan disease space. Initial clinical observations from treating physicians suggest a potential role for cannabinoids in addressing problems associated with ASD such as deficits in cognition, behavior, and ...
Manufactured by:EPED Inc. based inKaohsiung City, TAIWAN
The Most Flexible Augmented-Reality Simulator in Dental Clinical Training Education. SimEx is the most adaptive Augmented-Reality Simulator currently in today’s marketplace, enabling any dental school to select what typodont to use,and to customize the technology to their school’s speciï¬c ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of cancer death. The clinical candidate is a first-in-class, GPC3-FcA-LNP, with a strong preclinical profile supporting its advance into this ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent healthy cells. The DolaLock payload ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung ...
Manufactured by:TargetMol Chemicals Inc. based inWellesley Hills, MASSACHUSETTS (USA)
A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, ...
Manufactured by:Xtant Medical based inBelgrade, MONTANA (USA)
OsteoSelect was engineered for superior performance. The graft does not adhere to gloves yet maintains its placement in the surgical environment. Osteoinductivity of sterile final product is assessed in vivo. In this challenging model, every lot tested to date has consistently demonstrated an osteoinductive response. This performance validates Xtant Medical’s expertise in DBM processing. ...